An artificial intelligence (AI) tool developed by Annalise.ai Pty Ltd. was able to improve radiologists’ accuracy in detecting abnormalities on non-contrast computed tomography brain (CTB) scans. According to a study published in European Radiology, the Annalise Enterprise CTB module improved radiologists' accuracy by 32% and reduced their overall reading time by 11%.
Aiming to provide additional utility and information to its continuous glucose monitors (CGMs), Dexcom Inc. is tying in the nutrition information provided by Rxfood Corp.’s app for customers in Canada. Clinics, hospitals, pharmacies, health plans, employers and others can make the app available to the beneficiaries and patients who use the Dexcom G6 or G7 systems, once the program is rolled out.
Researchers from University Hospital Basel and Universitätsklinikum Ulm presented the discovery of novel radiotheragnostic candidates targeting C-X-C chemokine receptor 4 (CXCR4), which is highly expressed in various cancers and has been linked to poor prognosis.
Researchers from Huazhong University of Science and Technology presented the discovery and preclinical evaluation of a novel peptide PET tracer targeting LAG-3, [68Ga]NOTA-XH05, being developed as a candidate for evaluating the efficacy of cancer immunotherapy.
Researchers at Singapore’s Agency for Science Technology & Research Bioprocessing Technology Institute (also known as A*STAR BTI) saw publication of their patent application for a wearable electronic system for solid-state epidermal biomarkers (SEB) that enables in situ, continuous, multiplexed, wireless, and skin-integrated sensing of analytes such as cholesterol, lactate, and glucose.
Day Zero Diagnostics Inc. added more of the right kind of zeros to its coffers as it closed a $16 million financing round supported by existing investors. Venture capital investment in the diagnostics company to date totals $49 million, with more than $18 million in additional non-dilutive funding. The company is developing a diagnostic that provides same-day identification of an infectious pathogen and its antimicrobial susceptibility profile.
The discovery of new 68Ga-labeled CD38-targeted peptides for PET imaging was recently discussed by researchers from Peking University First Hospital and China National Center For Nanoscience & Technology.
Researchers from Peking University Cancer Hospital presented the discovery and preclinical evaluation of [124I]IMMU-132, a trophoblast cell surface antigen 2 (Trop2)-targeting molecular probe for micro-PET imaging.
Integrin alphavbeta3 and aminopeptidase N (CD13) are important biomarkers involved in tumor angiogenesis, tumor growth and metastasis. Peptides RGD (Arg-Gly-Asp) and NGR (Asn-Gly-Arg) are the most studied peptides for targeting integrin alphavbeta3 and CD13, respectively.
RSS
